For Healthcare Professionals

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma


About the study

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD7789 in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. ≥ 16 years of age at the time of obtaining informed consent
  2. Eastern Cooperative Oncology Group performance status of 0 or 1 at screening
  3. At least one PET-avid measurable lesion according to Modified Lugano Criteria after the last line of therapy.
  4. Confirmed histological diagnosis of active relapse/refractory cHL
  5. Failed at least 2 prior lines of systemic therapy.
  6. No previous treatment with anti-TIM-3.
  7. Adequate organ and bone marrow function
  8. Non-pregnant women and willingness of female patients to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of contraception
  9. Minimum body weight ≥ 40 kg for all participants.


Exclusion Criteria:

  1. Unresolved toxicities of ≥ Grade 2 from prior therapy
  2. Any prior ≥ Grade 3 imAE while receiving prior checkpoint inhibitor immunotherapy
  3. Patients with CNS involvement or leptomeningeal disease.
  4. History of organ transplantation (e.g., stem cell or solid organ transplant).
  5. Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose of study intervention.
  6. Active infection including TB, HIV, hepatitis A, chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19 infection
  7. History of arrhythmia which is requires treatment, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia
  8. Uncontrolled intercurrent illness.
  9. Active or prior documented pathologically confirmed autoimmune or inflammatory disorders.
  10. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
  11. Other invasive malignancy within 2 years prior to screening
  12. Congenital long QT syndrome or history of QT prolongation associated with other medications that cannot be changed or discontinued based on a cardiologist assessment
  13. Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study intervention
  14. Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Relapsed or Refractory Classical Hodgkin Lymphoma

Age (in years)

16 - 101


Phase 1/Phase 2

Participants needed


Est. Completion Date

Oct 15, 2027

Treatment type



AstraZeneca identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.